menu search

Biogen's (biib) lecanemab shows benefit but with side effects

Detailed data from Biogen (BIIB) and Eisai's Clarity AD shows that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rat...

November 30, 2022, 10:32 am

Wellbeing digital sciences subsidiary kgk science submits psilocybin and fragile x syndrome clinical trial application for client nova mentis

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said its wholly-owned subsidiary KGK Science Inc has submitted a clinical trial applicatio...

November 30, 2022, 9:21 am

Biogen stock up 3% premarket after update on alzheimer's treatment; stifel reiterates buy rating

Biogen Inc. stock BIIB, -0.17% rose 3% in premarket trade Wednesday, after a new study was unveiled late Tuesday that showed the company's experimenta...

November 30, 2022, 6:48 am

: a new alzheimer’s treatment may help some patients, though researchers say more safety data is needed

A new study found that Eisai and Biogen’s experimental Alzheimer’s drug moderately reduced cognitive...

November 30, 2022, 1:29 am

Eisai, biogen alzheimer's drug slows cognitive decline, safety for some becomes focus

New data was presented on Tuesday....

November 29, 2022, 7:55 pm

Verses announces proposed warrant amendments

VANCOUVER, British Columbia, Nov. 25, 2022 (GLOBE NEWSWIRE) — VERSES Technologies Inc. (NEO:VERS) (“VERSES” or the “Company”), a ...

November 25, 2022, 9:30 pm

Ericsson (eric) to boost 6g research capabilities in the uk

The initiative by Ericsson (ERIC) is likely to sow the seeds for in-depth 6G research activities on hardware security, AI, ...

November 22, 2022, 9:47 am

Ericsson to invest in 6g network research in britain

Networks equipment maker Ericsson said it would invest millions of pounds in 6G mobile research in Britain, working with universities on hardware secu...

November 22, 2022, 4:01 am

Inmune bio, high risk, higher reward.

The company has two clinical stage drugs with promising early results enjoying multiple use cases and facing multi-billion dollar market opportunities...

November 21, 2022, 12:45 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm


Search within

Pages Search Results: